Skip to main content
Equibles
BBIO logo

BBIO · BridgeBio Pharma, Inc. · Earnings Call Transcripts & Audio

Track BBIO — free

Use BBIO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BBIO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$66.71 +0.10 (+0.14%)
Russell 1000 member Rebalance outlook locked
Market Cap
$13.37B
Shares
195.49M

BridgeBio Pharma, Inc. Earnings Call Transcripts

Quarterly earnings calls for BridgeBio Pharma, Inc. (BBIO), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $54.02M −$102.07M '21 Q2 21-08-13 · $12.89M −$152.28M '21 Q4 22-03-14 ▲266.7% $1.69M −$201.33M '22 Q1 22-05-18 ▼85.5% $1.87M −$140.57M '22 Q4 23-02-23 ▼97.8% $1.64M −$160.70M '23 Q2 23-08-28 ▲1110.4% $4.09M −$179.49M '23 Q3 23-11-12 ▲11461.9% $211.12M −$36.16M '24 Q1 24-05-29 ▼33.2% $2.73M −$164.25M '24 Q3 24-11-23 ▲237.1% $5.88M −$267.39M '24 Q4 25-01-13 ▼44.8% $116.63M −$169.61M '25 Q1 25-04-29 ▲4999.9% $110.56M −$183.76M '25 Q2 25-08-05 ▲4318% $120.70M −$184.94M '25 Q3 25-10-29 ▲2521.2% $154.18M −$194.63M '25 Q4 26-02-24 ▲66.8% $194.51M −$166.56M '26 Q1 26-05-07 LATEST ▲120.4% $243.68M −$155.89M '26 Q2 26-08-10
Conference
Investor event
2026-09-09
BridgeBio Pharma, Inc. (BBIO) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-10
BridgeBio Pharma, Inc. (BBIO) Q2 2026 Earnings Call Transcript
Confident tone Late-stage pipeline / NDA submissions and PDUFA Ex-US commercialization vs. partnership strategy Path to profitability and operating leverage
Revenue
$243.68M
▲ 120.4% YoY
Diluted EPS
$-0.78
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-09
BridgeBio Pharma, Inc. (BBIO) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-04
BridgeBio Pharma, Inc. (BBIO) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-07
BridgeBio Pharma, Inc. (BBIO) Q1 2026 Earnings Call Transcript
Confident tone Atruvio (acoramidis) commercial momentum Encaleret in ADH1 and chronic hypoparathyroidism Infigratinib for achondroplasia
Revenue
$194.51M
▲ 66.8% YoY
Diluted EPS
$-0.84
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-03-10
BridgeBio Pharma, Inc. (BBIO) March 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-03-02
BridgeBio Pharma, Inc. (BBIO) March 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-02-24
BridgeBio Pharma, Inc. (BBIO) Q4 2025 Earnings Call Transcript
Confident tone Atruby / ATTR cardiomyopathy commercial launch Pipeline and Phase 3 catalysts Tafamidis IP risk
Revenue
$154.18M*
▲ 2521.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Conference
Investor event
2026-01-12
BridgeBio Pharma, Inc. (BBIO) January 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2025-12-03
BridgeBio Pharma, Inc. (BBIO) December 2025 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2025-11-18
BridgeBio Pharma, Inc. (BBIO) November 2025 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q3
2025-10-29
BridgeBio Pharma, Inc. (BBIO) Q3 2025 Earnings Call Transcript
Confident tone Attruby commercial performance Infigratinib in achondroplasia Encaleret Phase III CALIBRATE in ADH1
Revenue
$120.70M
▲ 4318% YoY
Diluted EPS
$-0.95
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
BridgeBio Pharma, Inc. (BBIO) Q2 2025 Earnings Call Transcript
Confident tone Attruby commercial launch Late-stage pipeline readouts Clinical differentiation and best-in-class data
Revenue
$110.56M
▲ 4999.9% YoY
Diluted EPS
$-0.95
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-04-29
BridgeBio Pharma, Inc. (BBIO) Q1 2025 Earnings Call Transcript
Confident tone Late-stage pipeline readouts Pipeline expansion indications TTR competitive positioning vs Acoramidis
Revenue
$116.63M
▼ 44.8% YoY
Diluted EPS
$-0.88
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-01-13
BridgeBio Pharma, Inc. (BBIO) Q4 2024 Earnings Call
Revenue
$5.88M*
▲ 237.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-23
BridgeBio Pharma, Inc. (BBIO) Q3 2024 Earnings Call
Revenue
$2.73M
▼ 33.2% YoY
Diluted EPS
$-0.86
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-29
BridgeBio Pharma, Inc. (BBIO) Q1 2024 Earnings Call
Revenue
$211.12M
▲ 11461.9% YoY
Diluted EPS
$-0.20
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q3
2023-11-12
BridgeBio Pharma, Inc. (BBIO) Q3 2023 Earnings Call
Revenue
$4.09M
▲ 1110.4% YoY
Diluted EPS
$-1.08
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-28
BridgeBio Pharma, Inc. (BBIO) Q2 2023 Earnings Call
Revenue
$1.64M
▼ 97.8% YoY
Diluted EPS
$-0.98
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-23
BridgeBio Pharma, Inc. (BBIO) Q4 2022 Earnings Call
Revenue
$1.87M*
▼ 85.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q1
2022-05-18
BridgeBio Pharma, Inc. (BBIO) Q1 2022 Earnings Call
Revenue
$1.69M
▲ 266.7% YoY
Diluted EPS
$-1.35
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-14
BridgeBio Pharma, Inc. (BBIO) Q4 2021 Earnings Call
Revenue
$12.89M*
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q2
2021-08-13
BridgeBio Pharma, Inc. (BBIO) Q2 2021 Earnings Call
Revenue
$54.02M
Diluted EPS
$-0.66
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-22
BridgeBio Pharma, Inc. (BBIO) Q4 2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q2
2020-08-11
BridgeBio Pharma, Inc. (BBIO) Q2 2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Showing 1–25 of 25 earnings calls
Key facts CIK 1743881 CUSIP 10806X102 13F (30d) 15 filings 12 filers Visit website Investor relations